Description:

ODM derived from http://clinicaltrials.gov/show/NCT00766779

Link:

http://clinicaltrials.gov/show/NCT00766779

Keywords:
Versions (2) ▾
  1. 12/6/13
  2. 4/16/14
Uploaded on:

April 16, 2014

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY 4.0
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Eligibility NCT00766779 Acute Myeloid Leukemia

Eligibility

  1. StudyEvent: Eligibility
    1. Eligibility
Inclusion Criteria
age 60 Years to 75 Years
primary or secondary AML as defined by WHO or refractory anemia with excess of blasts (RAEB)
First complete remission following one or two cycles of induction chemotherapy
Chemotherapy was administered according to current participating cooperative group protocols
Karnofsky performance status (assessment scale)
Written informed consent
Exclusion Criteria
AML FAB M3
HIV Seropositivity
Participation in another clinical trial without prior consent of the coordinating investigator, patients may exceptionally take part in a further study only if
The second study exclusively concerns induction therapy
Consolidation cycle one and two are given according to the accredited study group policy
No investigational drugs are used post registration for the HCT vs CT in elderly AML study.
Documentation for the HCT vs CT in elderly AML study is not compromised. Second hand data from foreign study is not accepted

Similar models